nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—ABL1—Parkinson's disease	0.524	0.693	CbGaD
Erlotinib—CYP2D6—Parkinson's disease	0.136	0.179	CbGaD
Erlotinib—ABCB1—Parkinson's disease	0.0969	0.128	CbGaD
Erlotinib—LTK—tongue—Parkinson's disease	0.00561	0.0622	CbGeAlD
Erlotinib—ULK3—tongue—Parkinson's disease	0.00305	0.0339	CbGeAlD
Erlotinib—Vandetanib—ABL1—Parkinson's disease	0.00249	0.703	CrCbGaD
Erlotinib—MAP2K5—hindbrain—Parkinson's disease	0.00162	0.018	CbGeAlD
Erlotinib—LTK—head—Parkinson's disease	0.00136	0.0151	CbGeAlD
Erlotinib—NR1I2—head—Parkinson's disease	0.00136	0.0151	CbGeAlD
Erlotinib—ULK3—forebrain—Parkinson's disease	0.00129	0.0144	CbGeAlD
Erlotinib—FLT3—cardiovascular system—Parkinson's disease	0.00127	0.0141	CbGeAlD
Erlotinib—ABL1—hindbrain—Parkinson's disease	0.00125	0.0139	CbGeAlD
Erlotinib—AURKC—head—Parkinson's disease	0.00118	0.013	CbGeAlD
Erlotinib—AURKC—nervous system—Parkinson's disease	0.00112	0.0124	CbGeAlD
Erlotinib—EPHA6—head—Parkinson's disease	0.00109	0.0121	CbGeAlD
Erlotinib—JAK3—head—Parkinson's disease	0.00109	0.0121	CbGeAlD
Erlotinib—AURKC—central nervous system—Parkinson's disease	0.00107	0.0119	CbGeAlD
Erlotinib—JAK3—nervous system—Parkinson's disease	0.00103	0.0115	CbGeAlD
Erlotinib—EPHA6—nervous system—Parkinson's disease	0.00103	0.0115	CbGeAlD
Erlotinib—MKNK1—cardiovascular system—Parkinson's disease	0.00103	0.0114	CbGeAlD
Erlotinib—HIPK4—brain—Parkinson's disease	0.000999	0.0111	CbGeAlD
Erlotinib—JAK3—central nervous system—Parkinson's disease	0.000995	0.011	CbGeAlD
Erlotinib—EPHA6—central nervous system—Parkinson's disease	0.000995	0.011	CbGeAlD
Erlotinib—MAP3K19—head—Parkinson's disease	0.00099	0.011	CbGeAlD
Erlotinib—LTK—brain—Parkinson's disease	0.000988	0.011	CbGeAlD
Erlotinib—PIP4K2C—medulla oblongata—Parkinson's disease	0.00098	0.0109	CbGeAlD
Erlotinib—JAK3—cerebellum—Parkinson's disease	0.000972	0.0108	CbGeAlD
Erlotinib—MAP3K19—nervous system—Parkinson's disease	0.000939	0.0104	CbGeAlD
Erlotinib—ULK3—medulla oblongata—Parkinson's disease	0.000936	0.0104	CbGeAlD
Erlotinib—MAP2K5—brainstem—Parkinson's disease	0.000929	0.0103	CbGeAlD
Erlotinib—MAP3K19—central nervous system—Parkinson's disease	0.000904	0.01	CbGeAlD
Erlotinib—PIP4K2C—midbrain—Parkinson's disease	0.000896	0.00993	CbGeAlD
Erlotinib—TNK1—cerebellum—Parkinson's disease	0.000893	0.0099	CbGeAlD
Erlotinib—MKNK1—medulla oblongata—Parkinson's disease	0.000881	0.00976	CbGeAlD
Erlotinib—PIP4K2C—spinal cord—Parkinson's disease	0.000874	0.00969	CbGeAlD
Erlotinib—ULK3—midbrain—Parkinson's disease	0.000855	0.00948	CbGeAlD
Erlotinib—AURKC—brain—Parkinson's disease	0.000853	0.00945	CbGeAlD
Erlotinib—STK10—cardiovascular system—Parkinson's disease	0.000849	0.00941	CbGeAlD
Erlotinib—ULK3—spinal cord—Parkinson's disease	0.000834	0.00925	CbGeAlD
Erlotinib—SLK—medulla oblongata—Parkinson's disease	0.000834	0.00925	CbGeAlD
Erlotinib—MKNK1—midbrain—Parkinson's disease	0.000805	0.00892	CbGeAlD
Erlotinib—EPHA6—brain—Parkinson's disease	0.00079	0.00876	CbGeAlD
Erlotinib—JAK3—brain—Parkinson's disease	0.00079	0.00876	CbGeAlD
Erlotinib—MKNK1—spinal cord—Parkinson's disease	0.000785	0.00871	CbGeAlD
Erlotinib—ABL1—embryo—Parkinson's disease	0.000782	0.00867	CbGeAlD
Erlotinib—PIP4K2C—head—Parkinson's disease	0.000777	0.00861	CbGeAlD
Erlotinib—FLT3—cerebellum—Parkinson's disease	0.000767	0.0085	CbGeAlD
Erlotinib—SLK—midbrain—Parkinson's disease	0.000762	0.00845	CbGeAlD
Erlotinib—MAP2K5—cardiovascular system—Parkinson's disease	0.000758	0.0084	CbGeAlD
Erlotinib—SLK—spinal cord—Parkinson's disease	0.000744	0.00824	CbGeAlD
Erlotinib—ULK3—head—Parkinson's disease	0.000741	0.00822	CbGeAlD
Erlotinib—PIP4K2C—nervous system—Parkinson's disease	0.000736	0.00816	CbGeAlD
Erlotinib—ABL2—cerebellum—Parkinson's disease	0.000732	0.00812	CbGeAlD
Erlotinib—TNK1—brain—Parkinson's disease	0.000725	0.00804	CbGeAlD
Erlotinib—MAP3K19—brain—Parkinson's disease	0.000718	0.00796	CbGeAlD
Erlotinib—ABL1—brainstem—Parkinson's disease	0.000716	0.00794	CbGeAlD
Erlotinib—EGFR—cerebellum—Parkinson's disease	0.000715	0.00792	CbGeAlD
Erlotinib—PIP4K2C—central nervous system—Parkinson's disease	0.000709	0.00786	CbGeAlD
Erlotinib—ULK3—nervous system—Parkinson's disease	0.000703	0.00779	CbGeAlD
Erlotinib—MKNK1—head—Parkinson's disease	0.000698	0.00774	CbGeAlD
Erlotinib—SLCO2B1—forebrain—Parkinson's disease	0.000697	0.00773	CbGeAlD
Erlotinib—PIP4K2C—cerebellum—Parkinson's disease	0.000693	0.00768	CbGeAlD
Erlotinib—ULK3—central nervous system—Parkinson's disease	0.000677	0.0075	CbGeAlD
Erlotinib—MKNK1—nervous system—Parkinson's disease	0.000662	0.00734	CbGeAlD
Erlotinib—ULK3—cerebellum—Parkinson's disease	0.000661	0.00733	CbGeAlD
Erlotinib—MAP2K5—medulla oblongata—Parkinson's disease	0.000648	0.00718	CbGeAlD
Erlotinib—MKNK1—central nervous system—Parkinson's disease	0.000637	0.00706	CbGeAlD
Erlotinib—MKNK1—cerebellum—Parkinson's disease	0.000623	0.0069	CbGeAlD
Erlotinib—Gefitinib—CYP2D6—Parkinson's disease	0.000612	0.173	CrCbGaD
Erlotinib—ABL2—brain—Parkinson's disease	0.000595	0.00659	CbGeAlD
Erlotinib—MAP2K5—midbrain—Parkinson's disease	0.000592	0.00656	CbGeAlD
Erlotinib—SLK—cerebellum—Parkinson's disease	0.00059	0.00654	CbGeAlD
Erlotinib—ABL1—cardiovascular system—Parkinson's disease	0.000585	0.00648	CbGeAlD
Erlotinib—EGFR—brain—Parkinson's disease	0.000581	0.00644	CbGeAlD
Erlotinib—MAP2K5—spinal cord—Parkinson's disease	0.000577	0.0064	CbGeAlD
Erlotinib—STK10—head—Parkinson's disease	0.000575	0.00637	CbGeAlD
Erlotinib—PIP4K2C—brain—Parkinson's disease	0.000563	0.00624	CbGeAlD
Erlotinib—STK10—nervous system—Parkinson's disease	0.000545	0.00604	CbGeAlD
Erlotinib—CYP2D6—hindbrain—Parkinson's disease	0.00054	0.00599	CbGeAlD
Erlotinib—ULK3—brain—Parkinson's disease	0.000537	0.00596	CbGeAlD
Erlotinib—STK10—central nervous system—Parkinson's disease	0.000525	0.00582	CbGeAlD
Erlotinib—MAP2K5—head—Parkinson's disease	0.000513	0.00569	CbGeAlD
Erlotinib—STK10—cerebellum—Parkinson's disease	0.000513	0.00568	CbGeAlD
Erlotinib—MKNK1—brain—Parkinson's disease	0.000506	0.00561	CbGeAlD
Erlotinib—SLCO2B1—medulla oblongata—Parkinson's disease	0.000504	0.00559	CbGeAlD
Erlotinib—ABL1—medulla oblongata—Parkinson's disease	0.0005	0.00554	CbGeAlD
Erlotinib—CYP1B1—cardiovascular system—Parkinson's disease	0.000495	0.00549	CbGeAlD
Erlotinib—MAP2K5—nervous system—Parkinson's disease	0.000487	0.00539	CbGeAlD
Erlotinib—SLK—brain—Parkinson's disease	0.000479	0.00531	CbGeAlD
Erlotinib—ORM1—spinal cord—Parkinson's disease	0.000469	0.0052	CbGeAlD
Erlotinib—MAP2K5—central nervous system—Parkinson's disease	0.000468	0.00519	CbGeAlD
Erlotinib—MAP2K5—cerebellum—Parkinson's disease	0.000458	0.00508	CbGeAlD
Erlotinib—ABL1—midbrain—Parkinson's disease	0.000457	0.00506	CbGeAlD
Erlotinib—SLCO2B1—spinal cord—Parkinson's disease	0.000449	0.00498	CbGeAlD
Erlotinib—ABL1—spinal cord—Parkinson's disease	0.000445	0.00494	CbGeAlD
Erlotinib—Gefitinib—ABCB1—Parkinson's disease	0.000437	0.124	CrCbGaD
Erlotinib—STK10—brain—Parkinson's disease	0.000416	0.00462	CbGeAlD
Erlotinib—SLCO2B1—head—Parkinson's disease	0.000399	0.00443	CbGeAlD
Erlotinib—ABL1—head—Parkinson's disease	0.000396	0.00439	CbGeAlD
Erlotinib—ORM1—nervous system—Parkinson's disease	0.000395	0.00438	CbGeAlD
Erlotinib—ORM1—central nervous system—Parkinson's disease	0.00038	0.00422	CbGeAlD
Erlotinib—SLCO2B1—nervous system—Parkinson's disease	0.000379	0.0042	CbGeAlD
Erlotinib—ABL1—nervous system—Parkinson's disease	0.000375	0.00416	CbGeAlD
Erlotinib—MAP2K5—brain—Parkinson's disease	0.000372	0.00412	CbGeAlD
Erlotinib—SLCO2B1—central nervous system—Parkinson's disease	0.000365	0.00404	CbGeAlD
Erlotinib—ABL1—central nervous system—Parkinson's disease	0.000361	0.00401	CbGeAlD
Erlotinib—SLCO2B1—cerebellum—Parkinson's disease	0.000356	0.00395	CbGeAlD
Erlotinib—ABL1—cerebellum—Parkinson's disease	0.000353	0.00392	CbGeAlD
Erlotinib—CYP1B1—head—Parkinson's disease	0.000335	0.00372	CbGeAlD
Erlotinib—CYP1B1—nervous system—Parkinson's disease	0.000318	0.00352	CbGeAlD
Erlotinib—ABCG2—medulla oblongata—Parkinson's disease	0.000315	0.00349	CbGeAlD
Erlotinib—CYP2D6—brainstem—Parkinson's disease	0.00031	0.00343	CbGeAlD
Erlotinib—CYP1B1—central nervous system—Parkinson's disease	0.000306	0.00339	CbGeAlD
Erlotinib—CYP1B1—cerebellum—Parkinson's disease	0.000299	0.00332	CbGeAlD
Erlotinib—CYP2D6—forebrain—Parkinson's disease	0.000299	0.00331	CbGeAlD
Erlotinib—SLCO2B1—brain—Parkinson's disease	0.000289	0.00321	CbGeAlD
Erlotinib—ABCG2—midbrain—Parkinson's disease	0.000288	0.00319	CbGeAlD
Erlotinib—ABL1—brain—Parkinson's disease	0.000287	0.00318	CbGeAlD
Erlotinib—ABCG2—spinal cord—Parkinson's disease	0.000281	0.00311	CbGeAlD
Erlotinib—ALB—brain—Parkinson's disease	0.000265	0.00294	CbGeAlD
Erlotinib—ABCB1—embryo—Parkinson's disease	0.000243	0.0027	CbGeAlD
Erlotinib—CYP1B1—brain—Parkinson's disease	0.000243	0.00269	CbGeAlD
Erlotinib—CYP1A1—head—Parkinson's disease	0.000237	0.00263	CbGeAlD
Erlotinib—CYP1A1—nervous system—Parkinson's disease	0.000225	0.00249	CbGeAlD
Erlotinib—ABCG2—cerebellum—Parkinson's disease	0.000223	0.00247	CbGeAlD
Erlotinib—CYP1A1—central nervous system—Parkinson's disease	0.000216	0.0024	CbGeAlD
Erlotinib—ABCB1—forebrain—Parkinson's disease	0.000215	0.00238	CbGeAlD
Erlotinib—CYP2C8—brain—Parkinson's disease	0.000186	0.00206	CbGeAlD
Erlotinib—ABCB1—cardiovascular system—Parkinson's disease	0.000182	0.00202	CbGeAlD
Erlotinib—ABCG2—brain—Parkinson's disease	0.000181	0.00201	CbGeAlD
Erlotinib—CYP1A1—brain—Parkinson's disease	0.000172	0.0019	CbGeAlD
Erlotinib—CYP2D6—head—Parkinson's disease	0.000171	0.0019	CbGeAlD
Erlotinib—CYP3A4—nervous system—Parkinson's disease	0.000165	0.00183	CbGeAlD
Erlotinib—CYP2D6—nervous system—Parkinson's disease	0.000162	0.0018	CbGeAlD
Erlotinib—CYP3A4—central nervous system—Parkinson's disease	0.000159	0.00176	CbGeAlD
Erlotinib—CYP2D6—central nervous system—Parkinson's disease	0.000156	0.00173	CbGeAlD
Erlotinib—ABCB1—medulla oblongata—Parkinson's disease	0.000155	0.00172	CbGeAlD
Erlotinib—CYP2D6—cerebellum—Parkinson's disease	0.000153	0.00169	CbGeAlD
Erlotinib—ABCB1—midbrain—Parkinson's disease	0.000142	0.00157	CbGeAlD
Erlotinib—ABCB1—spinal cord—Parkinson's disease	0.000139	0.00154	CbGeAlD
Erlotinib—CYP2D6—brain—Parkinson's disease	0.000124	0.00138	CbGeAlD
Erlotinib—ABCB1—head—Parkinson's disease	0.000123	0.00136	CbGeAlD
Erlotinib—ABCB1—nervous system—Parkinson's disease	0.000117	0.00129	CbGeAlD
Erlotinib—ABCB1—central nervous system—Parkinson's disease	0.000112	0.00125	CbGeAlD
Erlotinib—ABCB1—cerebellum—Parkinson's disease	0.00011	0.00122	CbGeAlD
Erlotinib—ABCB1—brain—Parkinson's disease	8.92e-05	0.000989	CbGeAlD
Erlotinib—ALB—Metabolism—GSTA4—Parkinson's disease	1.25e-05	8.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HTR2A—Parkinson's disease	1.25e-05	8.34e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—MAPK8—Parkinson's disease	1.25e-05	8.32e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HTR1A—Parkinson's disease	1.25e-05	8.32e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	1.24e-05	8.29e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PLA2G6—Parkinson's disease	1.24e-05	8.25e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	1.23e-05	8.25e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CYP2E1—Parkinson's disease	1.23e-05	8.2e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TAC1—Parkinson's disease	1.23e-05	8.19e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MAOB—Parkinson's disease	1.22e-05	8.17e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MAPK8—Parkinson's disease	1.22e-05	8.12e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—NQO1—Parkinson's disease	1.21e-05	8.11e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—OMD—Parkinson's disease	1.21e-05	8.07e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TALDO1—Parkinson's disease	1.21e-05	8.07e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—DRD1—Parkinson's disease	1.2e-05	8.03e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—COMT—Parkinson's disease	1.2e-05	8.01e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—TH—Parkinson's disease	1.2e-05	7.99e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GSTP1—Parkinson's disease	1.19e-05	7.97e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—IL6—Parkinson's disease	1.19e-05	7.96e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—MAOA—Parkinson's disease	1.19e-05	7.95e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—HMOX1—Parkinson's disease	1.18e-05	7.86e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—DRD3—Parkinson's disease	1.16e-05	7.78e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	1.16e-05	7.77e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—DDC—Parkinson's disease	1.16e-05	7.75e-05	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	1.15e-05	7.7e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CYCS—Parkinson's disease	1.15e-05	7.67e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NDUFB11—Parkinson's disease	1.15e-05	7.65e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PLA2G6—Parkinson's disease	1.13e-05	7.56e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ABCB1—Parkinson's disease	1.13e-05	7.55e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PLA2G6—Parkinson's disease	1.13e-05	7.52e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MAOB—Parkinson's disease	1.12e-05	7.49e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—COMT—Parkinson's disease	1.12e-05	7.47e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—TNF—Parkinson's disease	1.12e-05	7.46e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MAOB—Parkinson's disease	1.11e-05	7.44e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GSTP1—Parkinson's disease	1.11e-05	7.43e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—MAOA—Parkinson's disease	1.11e-05	7.42e-05	CbGpPWpGaD
Erlotinib—MKNK1—Disease—IL6—Parkinson's disease	1.11e-05	7.4e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—HMOX1—Parkinson's disease	1.1e-05	7.33e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GSTM1—Parkinson's disease	1.1e-05	7.33e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTA4—Parkinson's disease	1.1e-05	7.32e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—DDC—Parkinson's disease	1.09e-05	7.3e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GCH1—Parkinson's disease	1.09e-05	7.3e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—INS—Parkinson's disease	1.09e-05	7.29e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ADRBK1—Parkinson's disease	1.09e-05	7.26e-05	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—IL6—Parkinson's disease	1.08e-05	7.2e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	1.07e-05	7.13e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—MAPK8—Parkinson's disease	1.06e-05	7.11e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	1.06e-05	7.09e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ABCB1—Parkinson's disease	1.05e-05	7.04e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HTR7—Parkinson's disease	1.05e-05	7.03e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—DRD2—Parkinson's disease	1.05e-05	7.03e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MTHFR—Parkinson's disease	1.05e-05	7.03e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GPX1—Parkinson's disease	1.05e-05	7.01e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTA4—Parkinson's disease	1.03e-05	6.9e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Parkinson's disease	1.03e-05	6.88e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GSTM1—Parkinson's disease	1.02e-05	6.83e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—COMT—Parkinson's disease	1.02e-05	6.8e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GSTP1—Parkinson's disease	1.01e-05	6.76e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—MAOA—Parkinson's disease	1.01e-05	6.75e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—HMOX1—Parkinson's disease	9.99e-06	6.67e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CASP3—Parkinson's disease	9.97e-06	6.66e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—IL6—Parkinson's disease	9.91e-06	6.62e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PLA2G6—Parkinson's disease	9.87e-06	6.59e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GPX1—Parkinson's disease	9.8e-06	6.54e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—APOE—Parkinson's disease	9.79e-06	6.54e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MAOB—Parkinson's disease	9.77e-06	6.52e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GBA—Parkinson's disease	9.74e-06	6.5e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—DBH—Parkinson's disease	9.74e-06	6.5e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—FBP1—Parkinson's disease	9.74e-06	6.5e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—MTHFR—Parkinson's disease	9.69e-06	6.47e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP2D6—Parkinson's disease	9.62e-06	6.42e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ABCB1—Parkinson's disease	9.59e-06	6.4e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TNF—Parkinson's disease	9.54e-06	6.37e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CTGF—Parkinson's disease	9.44e-06	6.31e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GSTM1—Parkinson's disease	9.31e-06	6.22e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PLA2G6—Parkinson's disease	9.3e-06	6.21e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—DDC—Parkinson's disease	9.26e-06	6.19e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MAOB—Parkinson's disease	9.2e-06	6.15e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MAPK8—Parkinson's disease	9.17e-06	6.12e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CYP2D6—Parkinson's disease	9.09e-06	6.07e-05	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL6—Parkinson's disease	9.05e-06	6.05e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—MTHFR—Parkinson's disease	9.04e-06	6.04e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—APOE—Parkinson's disease	9.02e-06	6.03e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—IL6—Parkinson's disease	9.01e-06	6.02e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CTGF—Parkinson's disease	8.92e-06	5.96e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GPX1—Parkinson's disease	8.91e-06	5.95e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IGF2—Parkinson's disease	8.83e-06	5.89e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP2E1—Parkinson's disease	8.8e-06	5.88e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTA4—Parkinson's disease	8.75e-06	5.84e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NQO1—Parkinson's disease	8.7e-06	5.81e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	8.64e-06	5.77e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TH—Parkinson's disease	8.57e-06	5.73e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IGF1R—Parkinson's disease	8.53e-06	5.7e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—EDN1—Parkinson's disease	8.43e-06	5.63e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—APOE—Parkinson's disease	8.42e-06	5.62e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—INS—Parkinson's disease	8.37e-06	5.59e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP2D6—Parkinson's disease	8.33e-06	5.56e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CYP2E1—Parkinson's disease	8.31e-06	5.55e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP2D6—Parkinson's disease	8.29e-06	5.53e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYCS—Parkinson's disease	8.23e-06	5.5e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—MTHFR—Parkinson's disease	8.23e-06	5.49e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NQO1—Parkinson's disease	8.22e-06	5.49e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CTGF—Parkinson's disease	8.18e-06	5.46e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CTGF—Parkinson's disease	8.13e-06	5.43e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CASP3—Parkinson's disease	8.13e-06	5.43e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TH—Parkinson's disease	8.1e-06	5.41e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—IL6—Parkinson's disease	7.96e-06	5.31e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL1B—Parkinson's disease	7.91e-06	5.28e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PLA2G6—Parkinson's disease	7.88e-06	5.26e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MAOB—Parkinson's disease	7.8e-06	5.21e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CYCS—Parkinson's disease	7.78e-06	5.19e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IL6—Parkinson's disease	7.76e-06	5.18e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NGF—Parkinson's disease	7.75e-06	5.18e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—INS—Parkinson's disease	7.71e-06	5.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—IL6—Parkinson's disease	7.7e-06	5.14e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—APOE—Parkinson's disease	7.66e-06	5.11e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP2E1—Parkinson's disease	7.62e-06	5.09e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP2E1—Parkinson's disease	7.58e-06	5.06e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NQO1—Parkinson's disease	7.54e-06	5.03e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NQO1—Parkinson's disease	7.49e-06	5e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MAPK8—Parkinson's disease	7.47e-06	4.99e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TH—Parkinson's disease	7.43e-06	4.96e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	7.42e-06	4.96e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TH—Parkinson's disease	7.38e-06	4.93e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HTR2A—Parkinson's disease	7.38e-06	4.93e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—COMT—Parkinson's disease	7.29e-06	4.87e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP2D6—Parkinson's disease	7.26e-06	4.85e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MAPK8—Parkinson's disease	7.26e-06	4.85e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTP1—Parkinson's disease	7.26e-06	4.85e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MAOA—Parkinson's disease	7.24e-06	4.83e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—INS—Parkinson's disease	7.19e-06	4.8e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—HMOX1—Parkinson's disease	7.16e-06	4.78e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—DDC—Parkinson's disease	7.15e-06	4.77e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYCS—Parkinson's disease	7.13e-06	4.76e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CTGF—Parkinson's disease	7.13e-06	4.76e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYCS—Parkinson's disease	7.09e-06	4.73e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—COMT—Parkinson's disease	6.89e-06	4.6e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ABCB1—Parkinson's disease	6.87e-06	4.59e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—APOE—Parkinson's disease	6.86e-06	4.58e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTP1—Parkinson's disease	6.86e-06	4.58e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MAOA—Parkinson's disease	6.84e-06	4.57e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—IL6—Parkinson's disease	6.8e-06	4.54e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL1B—Parkinson's disease	6.76e-06	4.52e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—HMOX1—Parkinson's disease	6.76e-06	4.52e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTA4—Parkinson's disease	6.75e-06	4.51e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CTGF—Parkinson's disease	6.71e-06	4.48e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTM1—Parkinson's disease	6.67e-06	4.45e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP2E1—Parkinson's disease	6.64e-06	4.43e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NQO1—Parkinson's disease	6.57e-06	4.38e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—INS—Parkinson's disease	6.54e-06	4.37e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ABCB1—Parkinson's disease	6.49e-06	4.33e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TH—Parkinson's disease	6.47e-06	4.32e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GPX1—Parkinson's disease	6.39e-06	4.26e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—COMT—Parkinson's disease	6.31e-06	4.22e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTM1—Parkinson's disease	6.3e-06	4.21e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTP1—Parkinson's disease	6.29e-06	4.2e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—COMT—Parkinson's disease	6.28e-06	4.19e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MAOA—Parkinson's disease	6.27e-06	4.19e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	6.26e-06	4.18e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTP1—Parkinson's disease	6.25e-06	4.17e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MAOA—Parkinson's disease	6.23e-06	4.16e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYCS—Parkinson's disease	6.21e-06	4.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK8—Parkinson's disease	6.2e-06	4.14e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—HMOX1—Parkinson's disease	6.2e-06	4.14e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NQO1—Parkinson's disease	6.19e-06	4.13e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—HMOX1—Parkinson's disease	6.16e-06	4.12e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TH—Parkinson's disease	6.1e-06	4.07e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	6.08e-06	4.06e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GPX1—Parkinson's disease	6.03e-06	4.03e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MAOB—Parkinson's disease	6.02e-06	4.02e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ABCB1—Parkinson's disease	5.95e-06	3.97e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ABCB1—Parkinson's disease	5.92e-06	3.95e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MTHFR—Parkinson's disease	5.89e-06	3.94e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—INS—Parkinson's disease	5.86e-06	3.91e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYCS—Parkinson's disease	5.85e-06	3.91e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—Parkinson's disease	5.85e-06	3.91e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP2D6—Parkinson's disease	5.8e-06	3.87e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTM1—Parkinson's disease	5.78e-06	3.86e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTM1—Parkinson's disease	5.74e-06	3.84e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CTGF—Parkinson's disease	5.69e-06	3.8e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MTHFR—Parkinson's disease	5.57e-06	3.72e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GPX1—Parkinson's disease	5.53e-06	3.69e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—COMT—Parkinson's disease	5.5e-06	3.67e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GPX1—Parkinson's disease	5.5e-06	3.67e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—APOE—Parkinson's disease	5.49e-06	3.66e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTP1—Parkinson's disease	5.48e-06	3.66e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MAOA—Parkinson's disease	5.46e-06	3.65e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—HMOX1—Parkinson's disease	5.4e-06	3.61e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP2E1—Parkinson's disease	5.3e-06	3.54e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NQO1—Parkinson's disease	5.24e-06	3.5e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—COMT—Parkinson's disease	5.18e-06	3.46e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—APOE—Parkinson's disease	5.18e-06	3.46e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TH—Parkinson's disease	5.17e-06	3.45e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTP1—Parkinson's disease	5.16e-06	3.45e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MAOA—Parkinson's disease	5.15e-06	3.44e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MTHFR—Parkinson's disease	5.1e-06	3.41e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—HMOX1—Parkinson's disease	5.09e-06	3.4e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MTHFR—Parkinson's disease	5.08e-06	3.39e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTM1—Parkinson's disease	5.03e-06	3.36e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYCS—Parkinson's disease	4.96e-06	3.31e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ABCB1—Parkinson's disease	4.88e-06	3.26e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GPX1—Parkinson's disease	4.82e-06	3.22e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—Parkinson's disease	4.77e-06	3.19e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—APOE—Parkinson's disease	4.75e-06	3.17e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTM1—Parkinson's disease	4.74e-06	3.17e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—APOE—Parkinson's disease	4.72e-06	3.16e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—INS—Parkinson's disease	4.69e-06	3.13e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—Parkinson's disease	4.63e-06	3.09e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GPX1—Parkinson's disease	4.54e-06	3.03e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	4.47e-06	2.99e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MTHFR—Parkinson's disease	4.45e-06	2.97e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—INS—Parkinson's disease	4.43e-06	2.96e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—COMT—Parkinson's disease	4.39e-06	2.93e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CTGF—Parkinson's disease	4.39e-06	2.93e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTP1—Parkinson's disease	4.37e-06	2.92e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CASP3—Parkinson's disease	4.36e-06	2.91e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MAOA—Parkinson's disease	4.36e-06	2.91e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—Parkinson's disease	4.33e-06	2.89e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HMOX1—Parkinson's disease	4.31e-06	2.88e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MTHFR—Parkinson's disease	4.19e-06	2.8e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—APOE—Parkinson's disease	4.14e-06	2.76e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ABCB1—Parkinson's disease	4.14e-06	2.76e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	4.09e-06	2.73e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—INS—Parkinson's disease	4.06e-06	2.71e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NQO1—Parkinson's disease	4.04e-06	2.7e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—INS—Parkinson's disease	4.04e-06	2.7e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTM1—Parkinson's disease	4.02e-06	2.68e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK8—Parkinson's disease	4.01e-06	2.68e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TH—Parkinson's disease	3.99e-06	2.66e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—Parkinson's disease	3.96e-06	2.64e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—APOE—Parkinson's disease	3.9e-06	2.61e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GPX1—Parkinson's disease	3.85e-06	2.57e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYCS—Parkinson's disease	3.83e-06	2.56e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—Parkinson's disease	3.66e-06	2.44e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MTHFR—Parkinson's disease	3.55e-06	2.37e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—INS—Parkinson's disease	3.54e-06	2.36e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—COMT—Parkinson's disease	3.39e-06	2.26e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTP1—Parkinson's disease	3.37e-06	2.25e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MAOA—Parkinson's disease	3.37e-06	2.25e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—INS—Parkinson's disease	3.33e-06	2.23e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HMOX1—Parkinson's disease	3.33e-06	2.22e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—APOE—Parkinson's disease	3.3e-06	2.21e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ABCB1—Parkinson's disease	3.19e-06	2.13e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTM1—Parkinson's disease	3.1e-06	2.07e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GPX1—Parkinson's disease	2.97e-06	1.98e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—INS—Parkinson's disease	2.82e-06	1.89e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTHFR—Parkinson's disease	2.74e-06	1.83e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—Parkinson's disease	2.56e-06	1.71e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—APOE—Parkinson's disease	2.55e-06	1.7e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—INS—Parkinson's disease	2.18e-06	1.46e-05	CbGpPWpGaD
